BPI-fold containing Family A member 1 (Bpifa1) Role in IFN Driven Pulmonary Response

S. Khanal (New Haven, United States of America), N. Niu (New Haven, United States of America), L. Sharma (New Haven, United States of America), W. Liu (New Haven, United States of America), L. Cohn (New Haven, United States of America), C. Dela Cruz (New haven, United States of America), C. Britto (New Haven, United States of America)

Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations
Session: Host-microbe interactions in lung disease and exacerbations
Session type: Thematic Poster
Number: 2385
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Khanal (New Haven, United States of America), N. Niu (New Haven, United States of America), L. Sharma (New Haven, United States of America), W. Liu (New Haven, United States of America), L. Cohn (New Haven, United States of America), C. Dela Cruz (New haven, United States of America), C. Britto (New Haven, United States of America). BPI-fold containing Family A member 1 (Bpifa1) Role in IFN Driven Pulmonary Response. 2385

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis
Source: International Congress 2017 – New insights into pathogenesis of lung disease 
Year: 2017

BPI Fold Containing Family A Member 1 (BPIFA1) regulates mucosal microbiota and basal Interferon signaling
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018



Clinical Evidence for Targeted Strategies in Asthma with Type 2 Inflammation: Single and Dual Inhibition
Source: International Congress 2017 – Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics
Year: 2017

Biology and Role of Type 2 Airway Inflammation
Source: International Congress 2017 – Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics
Year: 2017

Role of TLR2 Polymorphism (2258) in Susceptibility to Pulmonary Tuberculosis
Source: International Congress 2019 – Tuberculosis: from basic science to patient care
Year: 2019

Sputum IL-26 Is Overexpressed in Severe Asthma and Induces Proinflammatory Cytokine Production and Th17 Cell Generation: A Case–Control Study of Women
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020


Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block.
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


A Study on Various Types of Presentations of Paediatric Tuberculosis and Response to  Fixed Dose Combination (FDC).
Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis
Year: 2020


Acute phase protein alpha1-antitrypsin - A novel regulator of angiopoietin-like protein 4 transcription and secretion in human cells
Source: International Congress 2014 – Mechanisms of COPD: proteases and a whole lot more
Year: 2014


Implication of Enhancer of Zeste Homolog 2 in Pulmonary Arterial Hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019

Association of the Monocyte Chemoattractant Protein 1 and Chemokine Receptor 2 Genetic Polymorphisms with Non-small Cell Lung Cancer in Taiwan
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017


Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study.
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Effects of Pulmonary Rehabilitation (PR) on Exercise Capacity (EC) and Quality of Life (QOL) in Indian Patients with Severe COPD
Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD
Year: 2017

Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019

Selection of patients from Pulmonary Rehabilitation (PR) to Disease Management (DM) programmes
Source: International Congress 2017 – Latest insights into the management of chronic lung diseases
Year: 2017

Aerobic Exercise Effects in Severe Asthma: Involvement of Lung Fibroblast (MRC-5) Cells and Kinins Signaling
Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease
Year: 2021

Workshop 3 - Pulmonary Function Tests
Source: Research Seminar 2012 - Preparing for the first early pulmonary intervention studies in infants and preschool childrenwith Cystic Fibrosis
Year: 2012

Late Breaking Abstract - ACE2 Overexpression Modulates Nicotine Receptors In Cell Type Specific Manner: Possible Relevance In Covid-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Patient and Public Involvement (PPI) in TANDEM: A Tailored intervention for ANxiety and DEpression Management in COPD
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017


Interleukin 6, as a « Target Molecule » ,in the Assessement of The Severity of SARS-2 COVID Infection
Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors
Year: 2021